Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain, and pruritus are managed. The Company aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.
Net income (FY, 2018)
EBIT (FY, 2018)
Market capitalization (13-Mar-2019)
Closing stock price (13-Mar-2019)
When was Cara Therapeutics founded?
Cara Therapeutics was founded in 2004.
Who are Cara Therapeutics key executives?
Cara Therapeutics's key executives are Derek Chalmers, Mani Mohindru and Michael E. Lewis.
How many employees does Cara Therapeutics have?
Cara Therapeutics has 37 employees.
What is Cara Therapeutics revenue?
Latest Cara Therapeutics annual revenue is $13.5 m.
What is Cara Therapeutics revenue per employee?
Latest Cara Therapeutics revenue per employee is $364 k.
Who are Cara Therapeutics competitors?
Competitors of Cara Therapeutics include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.
Where is Cara Therapeutics headquarters?
Cara Therapeutics headquarters is located at 4 Stamford Ave, Stamford.
Where are Cara Therapeutics offices?
Cara Therapeutics has an office in Stamford.
How many offices does Cara Therapeutics have?
Cara Therapeutics has 1 office.